First Urology is committed to providing world-class service in every aspect of patient care.
First Urology Clinical Research offers two locations for patient convenience, which are located at our main office in Jeffersonville, IN and our Dupont Square office in Louisville, KY. Both locations include separate patient waiting rooms, exam rooms and conference areas. The center offers on-site CT scans, ultrasonography, prostate ultrasonography with biopsy and cytoscopy, urodynamics and bladder scans.
The medical director, James L. Bailen, M.D., F.A.C.S., CPI, is board certified in urology and began conducting clinical research in 1995. Debbie Johnson, CCRC, is the Director of Research. The facility has been involved in multiple phase II and phase III trials for the study of:
- Bladder cancer
- Erectile dysfunction
- Interstitial cystitis
- Osteoporosis secondary to androgen deprivation therapy
- Overactive bladder
- Prostate cancer treatment and prevention
- Prostate intraepithelial neoplasia
- Stress and urge
- Stress urinary incontinence
- Urinary tract infections
For answers to frequently asked questions about clinical trials, visit ClinicalTrials.gov.
To learn more about First Urology Clinical Research, contact Debbie Johnson, CCRC, Director of Research, at (812) 206-8161 or email@example.com today.
The TAVT-45 Study
Recently diagnosed with metastatic prostate cancer?
First Urology is participating in a clinical research study comparing the effects of a new study drug (called TAVT-45) with a commercially available drug, known as Zytiga. While both contain the same active ingredient (abiraterone acetate), Zytiga is in tablets and TAVT-45 is mixed with water/juice to drink.
You may be eligible for this study if you:
- Are over 18 years of age
- Have been recently diagnosed with either castrate-sensitive or castrate-resistant metastatic prostate cancer
- Are able to travel to the study site for periodic visits over a 3-month period
Participants will receive study related care at no cost, and reasonable travel expenses will be paid for all trips to the study site.
If you feel you may qualify and wish to participate, please contact our coordinator at 812-206-8166.
The Apollo Study
Overactive Bladder (OAB) with Urinary Incontinence (UI) occurs when you cannot control the muscle contractions of your bladder and urine leaks unexpectedly. It’s a condition that can cause extreme inconvenience on your everyday life.
First Urology is participating in a study for OAB. The Apollo Study, which is enrolling now, is researching a new investigational drug for OAB.
You May Be Eligible for This Study If You:
- Are 18 to 75 years old
- Have had symptoms of OAB with Urinary Incontinence for a period of at least 6 months
- Had an inadequate response or limiting side effects to previous treatments